

Memorandum of Agreement
Trial to Assess Chelation Therapy (TACT)
Grant Number: 1 U01 AT001156
CFDA Number: 93.213 Research and Training in Complementary and Alternative
Medicine
Study Sponsors: National Institutes of Health (NCCAM and NHLBI)
Initial Award Date: 8/15/2002

AMENDMENT

This document amends the agreement between Mount Sinai Medical Center of Florida, Inc. located at 4300 Alton Road, Miami Beach, FL 33140 (hereinafter "Mount Sinai") and _____ the "Enrolling Center", located at _____ and _____ M.D. or D.O. (hereinafter the "Participating Investigator") in support of the clinical trial, "Trial to Assess Chelation Therapy" awarded to Mount Sinai by the National Institutes of Health (hereinafter "NIH") with Gervasio A. Lamas, M.D., Trial Chairman and Principal Investigator at Mount Sinai Medical Center of Florida, Inc.

All terms and conditions of the original agreement remain in effect with the exception of the section listed below.

10. Financial Management

Enrolling Center shall abide by the financial management guidelines and audit requirements in accordance with OMB Circular A-133, reporting record retention, and other requirements, as presently written or as later amended.

Additionally, Mount Sinai reserves the right to refuse study participation based on information received from the Site Investigator and Sub-Investigator Professional History Form.

IN WITNESS WHEREOF the parties have authorized their officers or representatives to execute this Amendment to the Agreement as of the date and the year indicated below the signatures.

For Institution

By: _____

Title: _____

Date: _____

For Mount Sinai Medical Center of Florida, Inc.

By: _____

Paul Katz, MD

Title: VP of Academic and Research Affairs

Date: _____

Gervasio A. Lamas, M.D.
Study Chairman

Date: _____

